PAOPA, a potent analogue of Pro-Leu-glycinamide and allosteric modulator of the dopamine D2 receptor, prevents NMDA receptor antagonist (MK-801)-induced deficits in social interaction in the rat: Implications for the treatment of negative symptoms in schizophrenia

Bailee Dyck, Kelly Guest, Christal Sookram, Dipannita Basu, Rodney Johnson, Ram K. Mishra

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

The aim of this study was to investigate whether a potent analogue of the endogenous brain peptide l-prolyl- l-leucyl-glycinamide (PLG), (3(R)-[(2(S)-pyrrolidinylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA), can prevent the induction of social withdrawal caused by sub-chronic treatment with the non-competitive NMDA (N-methyl- l-aspartate) receptor antagonist, MK-801.Results indicate that MK-801 (0.5. mg/kg) significantly decreased social interaction following sub-chronic treatment (7. days). Treatment with PAOPA (1. mg/kg) blocked the effects of MK-801, and increased the amount of time spent in social interaction in comparison to control animals. These results provide evidence for the development of peptidomimetic compounds for the treatment of social withdrawal and related negative symptoms associated with schizophrenia.

Original languageEnglish (US)
Pages (from-to)88-92
Number of pages5
JournalSchizophrenia Research
Volume125
Issue number1
DOIs
StatePublished - Jan 2011

Keywords

  • Dopamine D2 receptor
  • MK-801
  • Non-competitive NMDA antagonist
  • PAOPA
  • Social interaction

Fingerprint Dive into the research topics of 'PAOPA, a potent analogue of Pro-Leu-glycinamide and allosteric modulator of the dopamine D2 receptor, prevents NMDA receptor antagonist (MK-801)-induced deficits in social interaction in the rat: Implications for the treatment of negative symptoms in schizophrenia'. Together they form a unique fingerprint.

  • Cite this